


Clinical Implementation of New PET Reconstruction Methods

Daniel McGowan

Head of Education and Research, Consultant Clinical Scientist
Department of Medical Physics and Clinical Engineering, Oxford University Hospitals
Honorary Senior Clinical Research Fellow, Department of Oncology, University of Oxford

PET image reconstruction

- Evolution of image reconstruction methods
 - FBP
 - OSEM
 - OSEM TOF
 - OSEM+PSF TOF
 - DDG**
 - MAP (GE – Q.Clear)**
 - AI (GE – PDL, United – uAI HYPER, Siemens – FastPET)**
 - Your work!**





MAP: GE Implementation

- Marketed as 'Q.Clear'
- One variable for users to optimise
 - Higher beta gives greater noise suppression


$$\hat{\mathbf{x}} = \arg \max_{\mathbf{x} \geq 0} \sum_{i=1}^{n_d} y_i \log [P\mathbf{x}]_i - [P\mathbf{x}]_i - \beta \sum_{j=1}^{n_v} \sum_{k \in N_j} \kappa_{jk} \phi(\mathbf{x}_j - \mathbf{x}_k)$$


- What is the impact on clinical images...

62M, FDG




75M, F-choline






Oxford University Hospitals
NHS Foundation Trust




Phantom Testing


Oxford University Hospitals
NHS Foundation Trust

- Use NEMA IQ. Sphere: background 4:1





B200 **B300** **B400** **B500** **OSEM**

NHS hospitals NHS Foundation Trust

- Radiologist blind scoring

Parameter	Highest-ranked reconstruction (% of cases)	
	Scorer 1	Scorer 2
Overall IQ	B400 (87%)	B400 (73%)


B200 **B300** **B400** **B500** **OSEM**

Clinical Testing


- Use prior patient sinograms



- Series of histological proven cancer types
- **Blind** radiologist scoring



**Novel penalised likelihood reconstruction of PET
in the assessment of histologically verified small
pulmonary nodules**



N=121 nodules

Conclusion

The use of BPL, an iterative reconstruction technique using a Bayesian penalised likelihood reconstruction algorithm, results in a significant increase in signal-to-noise and signal-to-background measures in comparison to conventional OSEM reconstruction. While it does not improve the overall accuracy of 18F-FDG PET/CT for differentiating benign from malignant nodules, it appears to provide a more accurate report on the metabolic activity of the nodules. When a semi-quantitative analysis

11mm left upper lobe adenocarcinoma


OSEM

MAP

3 histologically-proven colorectal liver metastases

23M...184Kg


NHS
Oxford University Hospitals
NHS Foundation Trust




- Patient weight significantly impacts IQ
- Increase in weight leads to increase in noise
- Different dosing regime and bed times have been tested...still poorer IQ for obese patients


23M...184Kg

NHS
Oxford University Hospitals
NHS Foundation Trust





Clinical Papers




Oxford University Hospitals
NHS Foundation Trust

Eur Radiol (2016) 26:576–584
DOI 10.1007/s00330-015-3832-y

NUCLEAR MEDICINE

**Novel p
in the as
pulmon:**



Eugene J. Teo
Elizabeth Bek

Eur Radiol
DOI 10.1007/s00330-4

NUCLEAR MEI

Received: 23 Dec
© The Author(s)

Does a nc
improve: **18F-FDG**
**mediastin:
using a pe**

Nassim Parv
Kevin M. Br

^a Department of Clin
^b Department of Onc
^c Radiation Physics c

Eugene J. Teoh^{1,2} · Daniel R. McGow
Edward Black⁴ · Alastair Moore⁵ · A

Anna K. Chilcc
Kevin M. Brad
Daniel R. McG

Received: 27 May 2015 / Revised: 23 Decemb
© The Author(s) 2016. This article is publishe


Nuclear Medicine and Molecular Imaging • Original Research

Effect of a Bayesian Penalized Likelihood PET Reconstruction Compared With Ordered Subset Expectation Maximization on Clinical Image Quality Over a Wide


Optimization of Image Reconstruction for ⁹⁰Y Selective Internal Radiotherapy on a Lutetium Yttrium Orthosilicate PET/CT System Using a Bayesian Penalized Likelihood Reconstruction Algorithm

Lisa M. Rowley¹, Kevin M. Bradley², Philip Boardman², Aida Hallam¹, and Daniel R. McGowan^{1,3}

¹Radiation Physics and Protection, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; ²Department of Radiology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; and ³Department of Oncology, University of Oxford, Oxford, United Kingdom



Clinical Papers



Oxford University Hospitals
NHS Foundation Trust

Phantom and Clinical Evaluation of the Bayesian Penalized Likelihood Reconstruction Algorithm Q.Clear on an LYSO PET/CT System

Eugene J. Teoh^{*1,2}, Daniel R. McGowan^{*2,3}, Ruth E. Macpherson¹, Kevin M. Bradley¹, and Fergus V. Gleeson^{1,2}

¹Department of Radiology, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom; ²Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, United Kingdom; and ³Radiation Physics and Protection, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Key Words: positron emission tomography; image reconstruction; Bayesian penalized likelihood; NEMA; image quality; optimization

J Nucl Med 2015; 56:1447–1452
DOI: 10.2967/jnumed.115.159301

Q.Clear, a Bayesian penalized-likelihood reconstruction algorithm for PET, was recently introduced by GE Healthcare on their PET scanners to improve clinical image quality and quantification. In this work, we determined the optimum penalization factor (beta) for


- Evidence in literature
- Many presentations
- Helpful having phantom **and** clinical scoring
- Build diagnostic confidence
- Also used for data driven gating evaluation


Data-Driven Respiratory Gating Outperforms Device-Based Gating for Clinical ¹⁸F-FDG PET/CT

Matthew D. Walker¹, Andrew J. Morgan¹, Kevin M. Bradley^{2,3}, and Daniel R. McGowan^{1,4}

¹Radiation Physics and Protection, Churchill Hospital, Oxford, United Kingdom; ²Department of Radiology, Churchill Hospital, Oxford, United Kingdom; ³Wales Research and Diagnostic PET Imaging Centre, Cardiff University, Cardiff, United Kingdom; and ⁴Department of Oncology, University of Oxford, Oxford, United Kingdom

J Nucl Med 2020; 61:1678-1683
DOI: 10.2967/jnumed.120.242248






Ungated 50%


SUV_{max} = 2.4


DDG


SUV_{max} = 3.8

Liver met only clearly visible on respiratory gated images









- However, with new technology people need to relearn!
- Perceived issue with lymphoma...

European Journal of Nuclear Medicine and Molecular Imaging (2018) 45:316-317
<https://doi.org/10.1007/s00259-017-3893-z>

Embrace Progress

LETTER TO THE EDITOR

Cite Kevin M. Bradley, Daniel R. McGowan, Fergus V. Gleeson, Geoffrey B. Johnson, Jason R. Young, Craig S. Levin, Guido A. Davidzon and Andrei H. Iagaru
Journal of Nuclear Medicine July 2018, 59 (7) 1169; DOI: <https://doi.org/10.2967/jnumed.118.212761>


All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting

Sally F. Barrington¹ • Tom Sulkin² • Adam Forbes³ • Peter W. M. Johnson⁴

- Sadly other manufacturers not using MAP, yet
- A range are trying AI enhancement
 - How to implement and trust these?

Precision DL – what is it?


- An image enhancement tool using deep learning
 - To make images “ToF-like”
 - Improved quantification
 - Improved lesion detectability




- Three ‘strengths’ that can be used depending on user preference (similar to beta)

Low Medium High

High noise input




Low noise input



Precision DL – how was it developed?

- *To trust need to know how developed!*
- 100s of paired FDG images – nonToF Q.Clear and ToF Q.Clear
- Multi-site & multi-scanners
- 3D residual U-net trained for each PDL strength




Testing PDL

- Before using an AI PET recon algorithm, there are several important tests you should consider conducting to ensure its suitability and performance. Here are some key tests you can consider:
 - Algorithm Validation
 - Performance Evaluation
 - Robustness Assessment
 - Comparison with standard methods
 - Clinical Validation
 - Generalisation testing
 - Safety and Regulatory Compliance
 - User Interface and Integration Testing

Testing PDL

- What did you think of those reasons?
- They were all written by chat GPT!

 What should I test before using AI PET recon algorithm

 Before using an AI PET recon algorithm, there are several important tests you should consider conducting to ensure its suitability and performance. Here are some key tests you can consider:


1. Algorithm Validation: Verify that the AI PET recon algorithm has been validated using a


Deep Learning PET Algorithms

- What do I (with clinical physics hat!) want before using?
- *Knowledge of how developed* ✓
- *Phantom testing*
- *Lesion Quantification*
- *Lesion Detectability*
- *Image Noise*
- *Potential over enhancement*
- *Robustness of algorithm*
- *FDA/CE marked device*

Testing PDL: Lesion Insertion

- Unable to really use phantoms – lesion insertion technique






Oxford University Hospitals
NHS Foundation Trust


Testing PDL: Lesion Insertion

- Ground truth known!


Q.Clear nonTOF




Q.Clear ToF



M-PDL



10 mm, 4:1 contrast lesion in the head/neck area of a DMI 25 cm exam.




Oxford University Hospitals
NHS Foundation Trust

Testing PDL: Accuracy

- Inserted lesions allow assessment of quantitation accuracy
- Accuracy comparison (n=32) using 10&15mm lesions in **DMI data**

Reconstruction method	Average % Accuracy SUVmean	Average % Accuracy SUVmax	Average liver noise (std)
Q.Clear nonToF	50	49	0.19
Q.Clear ToF	60	63	0.21
PDL-H	58	61	0.21




Oxford University Hospitals
NHS Foundation Trust

Testing PDL: Lesion Detectability


- Model Observer Detectability
- Also tested via human (n=3) scoring of patients (n=50)
- Time consuming! 250 PET scans (blinded to recon used) with CT

Likert scale

5 (excellent)
4 (very good)
3 (good)
2 (satisfactory)
1 (poor)
0 (non-diagnostic)



Method	Score (approx.)
QClear	3.0
PDL-L	2.9
PDL-M	4.0
PDL-H	4.2
QClear ToF	4.1



Oxford University Hospitals
NHS Foundation Trust

Testing PDL: Clinical Scoring

- Patient scan review (n=50)
- Diagnostic Confidence and Image noise (as well as Lesion Detectability)

Scores	Diagnostic confidence	Lesion detectability	Image noise/quality
Non-ToF BSREM	3.03 ± 0.40 (<0.001)	3.03 ± 0.43 (<0.001)	3.36 ± 0.40 (1.000)
DL-ToF(L)	2.98 ± 0.34 (<0.001)	2.88 ± 0.35 (<0.001)	4.52 ± 0.27 (<0.001)
DL-ToF(M)	4.07 ± 0.47 (<0.001)	3.99 ± 0.48 (1.000)	4.09 ± 0.34 (<0.001)
DL-ToF(H)	3.83 ± 0.38 (0.11)	4.18 ± 0.39 (1.000)	3.39 ± 0.40 (0.96)
ToF BSREM	3.53 ± 0.53	4.08 ± 0.54	3.08 ± 0.55
ICC	0.67 (0.60, 0.74)	0.68 (0.61, 0.74)	0.58 (0.48, 0.66)


5 (excellent)
4 (very good)
3 (good)
2 (satisfactory)
1 (poor)
0 (non-diagnostic)

European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:3740–3749
<https://doi.org/10.1007/s00259-022-05824-7>

ORIGINAL ARTICLE

Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans

Abolfazl Mehranian¹ · Scott D. Wollenweber² · Matthew D. Walker³ · Kevin M. Bradley⁴ · Patrick A. Fielding⁵ · Martin Huellner⁶ · Fotis Kotastidis⁷ · Kuan-Hao Su² · Robert Johnsen² · Floris P. Jansen² · Daniel R. McGowan^{3,8}




Testing PDL: Quantification

- Lesion SUVmax + VOIs in lung and liver

	Lesion SUV _{max} (%)	Lung SUV _{mean} (%)	Liver SUV _{mean} (%)	Liver noise (SUV)
Non-ToF BSREM	-28.6 ± 18.3 (<0.0001)	7.7 ± 15.0 (<0.0001)	4.3 ± 5.6 (<0.0001)	0.16
DL-ToF(L)	-28.7 ± 19.0 (<0.0001)	0.6 ± 12.1 (0.179)	0.7 ± 4.6 (0.067)	0.10
DL-ToF(M)	-8.0 ± 22.5 (<0.0001)	1.3 ± 13.0 (0.083)	0.8 ± 4.4 (0.016)	0.13
DL-ToF(H)	1.7 ± 23.9 (0.57)	1.4 ± 11.5 (0.50)	0.1 ± 4.5 (0.86)	0.19
ToF-BSREM	-	-	-	0.19


European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:3740–3749
<https://doi.org/10.1007/s00259-022-05824-7>

ORIGINAL ARTICLE



Deep learning-based time-of-flight (ToF) image enhancement of non-ToF PET scans


Abolfazl Mehranian¹ · Scott D. Wollenweber² · Matthew D. Walker³ · Kevin M. Bradley⁴ · Patrick A. Fielding⁵ · Martin Huellner⁶ · Fotis Kotasidis⁷ · Kuan-Hao Su² · Robert Johnsen² · Floris P. Jansen² · Daniel R. McGowan^{3,8}



Deep Learning PET Algorithms

- What do I (with clinical physics hat!) want before using?
 - Knowledge of how developed* ✓
 - ~~Phantom~~ Lesion insertion* ✓
 - Lesion Quantification* ✓
 - Lesion Detectability* ✓
 - Image Noise* ✓
 - Potential over enhancement (not shown)* ✓
 - Robustness of algorithm (not shown)* ✓
 - FDA/CE marked device* ✓


Many other tests performed not covered here!




April 27, 2023

GE Healthcare
 % George Mashour
 Senior Regulatory Affairs Manager
 GE Medical Systems Israel
 4 Hayozma Street
 Tirat Hacarmel, 30200
 ISRAEL

Re: K223212
 Trade/Device Name: Precision DL








Oxford University Hospitals
NHS Foundation Trust

Deep Learning PET Algorithms

- Happy with testing. Now to use with patients for better scans!
- Increasing use of AI in PET (and other modalities)
- Clinical staff may be unsure how to test
- Giving results from these sorts of tests would assist with clinical implementation










Oxford University Hospitals
NHS Foundation Trust

PET image reconstruction


European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:2711–2726
<https://doi.org/10.1007/s00259-021-05390-4>

CONTROVERSIES - FOR 


New PET technologies – embracing progress and pushing the limits

Nicolas Aide^{1,2}  · Charline Lasnon^{2,3} · Adam Kesner⁴ · Craig S Levin⁵ · Irene Buvat⁶ · Andrei Iagaru⁷ · Ken Hermann⁸ · Ramsey D Badawi⁹ · Simon R Cherry⁹ · Kevin M Bradley¹⁰ · Daniel R McGowan^{11,12} 

European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:2696–2710
<https://doi.org/10.1007/s00259-021-05403-2>

CONTROVERSIES - AGAINST 

Moving the goalposts while scoring—the dilemma posed by new PET technologies

Julian M.M. Rogasch^{1,2} · Ronald Boellaard³ · Lucy Pike⁴ · Peter Borchmann⁵ · Peter Johnson⁶ · Jürgen Wolf⁷ · Sally F. Barrington⁴ · Carsten Kobe⁸ 




Fig. 2

NHS
Oxford University Hospitals
NHS Foundation Trust

- We need to get new recons into the clinic
- Important to get clinical staff on board and understanding the underlying recon
- *“We look forward to all users embracing technology, now and in the future, for improved early diagnosis and detection and crucially the benefit of patient care”*
- **Please keep developing!**

Incidentally detected tiny, ¹⁸F-FDG avid breast nodule in a 70-year-old patient. Triple assessment (mammogram, ultrasound and breast examination) following PET was negative, but 3 months later a small (sub-centimetre) ductal cell breast carcinoma was detected and cured. SUV_{max} 1.8 on OSEM (a and b) and SUV_{max} 5.0 on BPL (c and d). PET images on an SUV scale 0–6

European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:2711–2726
https://doi.org/10.1007/s00259-021-05390-4

CONTROVERSIES - FOR

New PET technologies – embracing progress and pushing the limits

Nicolas Aide^{1,2} • Charline Lasnon^{2,3} • Adam Kesner⁴ • Craig S Levin⁵ • Irene Buvat⁶ • Andrei Iagaru⁷ • Ken Hermann⁸ • Ramsey D Badawi⁹ • Simon R Cherry⁹ • Kevin M Bradley¹⁰ • Daniel R McGowan^{11,12}

Oxford University Hospitals **NHS**
NHS Foundation Trust

Acknowledgements

NCIMI
National Consortium of Intelligent Medical Imaging

UNIVERSITY OF OXFORD

CARDIFF UNIVERSITY
PRIFYSGOL CAERDYDD

USZ Universitäts Spital Zürich

GE

Matt Walker
Meghi Dedja

Abolfazl Mehranian
Rob Johnsen
Scott Wollenweber
Moshe Levy
Floris Jansen
+ Many other staff at GE

Kevin Bradley
Patrick Fielding

Martin Hüllner



Thanks for listening

Any Questions?

daniel.mcgowan@oncology.ox.ac.uk

Teoh and Bradley QJM 2017